



**CRESO**  
PHARMA

**ASX Announcement**

22 November 2017

## **Creso Pharma announces major deal to import and distribute its first cannabinoid-based human health product in Australia in early CY2018**

### **Highlights:**

- **Creso Pharma secures major deal for the Australian import of its first cannabinoid-based human health product, cannaQIX®50, in early CY2018.**
- **Creso is partnering with Health House International to import and distribute cannaQIX®50 in Australia under local medicinal cannabis regulations.**
- **Move is part of Creso's overall corporate strategy to expand the international distribution of its products and expands its position in the Australian market.**
- **Follows Creso being the first Australian company to import medicinal cannabis to Australia in May 2017.**
- **cannaQIX®50 will support the management of chronic pain.**



**Creso Pharma Limited** (ASX:CPH, the “Company” or “Creso”) has secured an important deal with its Australian distribution partner, Health House International for the import of its first cannabinoid-based human health product, cannaQIX®50, in early CY2018.

Under the move, Health House will import and distribute the product under local medicinal cannabis regulations. Creso is also working with Australian State and Federal Government and health authorities.

The importation is part of Creso's overall corporate strategy to expand the international distribution of its products and cements the Company's position in the Australian market. It also augments Creso's local competitive advantage after it was the first Australian company to import medicinal cannabis into Australia in May 2017.

cannaQIX®50 is Creso's proprietary buccally formulated cannabidiol (CBD) lozenge product which is designed to support the management of chronic pain.

Once the product is imported, Health House International will distribute the product to pharmacies in all Australian states and territories. The lozenges will be available through the Therapeutic Goods Administration's (TGA) Special Access Scheme (SAS). The TGA administers the SAS which provides a pathway allowing eligible medical practitioners to apply for approval to prescribe medicinal cannabis products. As a prescription CBD product, physicians outside of Queensland and Tasmania only need to apply to the TGA for approval and not their respective state health authorities.



Each cannaQIX®50 lozenge contains 50mg of CBD from full hemp plant extracts along with niacin, vitamins B6, B12, C and zinc in a proprietary standardised pharma-grade formulation produced in Switzerland. They come in a pack of 30 lozenges.

The cannaQIX®50 lozenges have a delivery formulation designed for buccal absorption and dissolve in the mouth. This method works faster and more efficiently than tablets or capsules which need to be swallowed and have a high percentage of their ingredients broken down when absorbed through the intestine and passed first through the liver. By being dissolved in the mouth, the active ingredients enter the blood stream directly, avoiding this first pass through the liver.

“We are thrilled to be introducing our first Creso innovative human health product in Australia in CY2018 and are pleased to be one of the first companies to provide medicinal cannabis products to approved patients here. There is a considerable unmet patient need for innovative and more patient-friendly CBD products in Australia and our cannaQIX®50 product will provide patients with a pharmaceutical-grade, Process-certified and proprietary standardised formulation product,” said Creso Pharma CEO and Co-Founder, Dr. Miri Halperin Wernli.

“The move also cements our position in the Australian market and enhances our competitive position after being the first Australian company to import medicinal cannabis into Australia earlier this year.”

Health House International Director, Paul Mavor added: “An estimated 1 in 5 Australian adults suffer from chronic pain at huge costs to the healthcare system, their quality of life and their family and friends. Products like cannaQIX®50 are a game changer for Creso and Health House International. Its pharmaceutically sophisticated dosage form meets a current unmet need in CBD products and I believe it will be very successful with prescribers, patients and pharmacists alike because it doesn't require the need to calculate non-standardised drops for oil-based CBD products.”

“Working with Creso enables us to benefit from its wealth of international and pharmaceutical scientific expertise in the medicinal cannabis and CBD-based space. At the same time, we can provide Creso access to our extensive Australian distribution network and we look forward to helping launch Creso's other CBD-based products.”

Distribution agreements for other products from the cannaQIX® range are in advanced preparation in Switzerland, a number of key European countries (Germany, UK, Italy, Spain, Netherlands, Belgium, Sweden), as well as in Canada and Latin America.

### **About cannaQIX®**

The cannaQIX® series of products are standardised in composition and dose, come in innovative proprietary delivery systems to enhance bioavailability and absorption, and are produced in Switzerland by Creso's partner Swiss-based food and pharma development company, Domaco, Dr. med Aufdermaur AG (Domaco) to the highest Swiss quality.

This standardisation enables the cannaQIX® products to be used in research, such as through Creso's recently announced collaborative agreement with the University of Wollongong.

-ENDS-

**Investor Enquiries:**

Gabriella Hold  
M: 0411 364 382  
E: [gabriella.hold@mcpartners.com.au](mailto:gabriella.hold@mcpartners.com.au)

**Media Enquiries:**

Elise Hughan  
M: 0458 855 500  
E: [elise.hughan@mcpartners.com.au](mailto:elise.hughan@mcpartners.com.au)

**Corporate Queries:**

EverBlu Capital  
Level 39, Aurora Place  
88 Phillip Street, Sydney, NSW 2000  
E: [info@everblucapital.com](mailto:info@everblucapital.com)  
P: +61 2 8249 0000

**About Creso Pharma**

[www.cresopharma.com](http://www.cresopharma.com)

Creso Pharma brings pharmaceutical expertise and methodological rigour to the world of medicinal cannabis and strives for the highest quality in its products. It is the leader in medicinal cannabis and cannabidiol (CBD) innovation and develops cannabis- and hemp-derived therapeutic-grade nutraceuticals and medicinal cannabis products with wide patient and consumer reach for human and animal health. Creso uses GMP development and manufacturing standards for its products as a reference of quality excellence with initial product registrations in Switzerland. It has worldwide rights for a number of unique and proprietary innovative delivery technologies which enhance the bioavailability and absorption of cannabinoids.

**About Health House International**

Health House International is a medical cannabis wholesaler based in Perth, Western Australia, that services the Australian market. It is owned by pharmacist Paul Mavor who has been studying medical cannabis for his patients. He has been a pharmacist for 30 years and several years ago made the switch to researching and facilitating access to medicinal cannabis for patients full time.

**About Domaco, Dr. med Aufdermaur AG**

Domaco, Dr. med Aufdermaur AG is a Swiss-based food and pharma development company that owns the rights to a number of innovative delivery systems used to administer active ingredients through galenic forms which is a way of preparing and compounding medicines in order to optimise their absorption.